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A B S T R A C T
Background: Surgical myectomy and alcohol septal ablation (ASA) aim to decrease left ventricular
outﬂow tract (LVOT) gradient in hypertrophic cardiomyopathy (HCM). Outcome of myectomy beyond
10 years has rarely been described. We describe 20 years of follow-up of surgical myectomy and 5 years
of follow-up for ASA performed for obstructive HCM.
Methods: We studied 171 patients who underwent myectomy for symptomatic LVOT obstruction
between 1972 and 2006. In addition, we studied 52 patients who underwent ASA for the same indication
and who declined surgery. Follow-up of New York Heart Association (NYHA) functional class,
echocardiographic data, and vital status were obtained from patient records. Mortality rates were
compared with expected mortality rates of age- and sex-matched populations.
Results: Surgical myectomy improved NYHA class (2.74  0.65 to 1.54  0.74, p < 0.001), reduced resting
gradient (67.4  43.4 mmHg to 11.2  16.4 mmHg, p < 0.001), and inducible LVOT gradient (98.1 
34.7 mmHg to 33.6  34.9 mmHg, p < 0.001). Similarly, ASA improved functional class (2.99  0.35 to
1.5  0.74, p < 0.001), resting gradient (67.1  26.9 mmHg to 23.9  29.4 mmHg, p < 0.001) and provoked
gradient (104.4  34.9 mmHg to 35.5  38.6 mmHg, p < 0.001). Survival after myectomy at 5, 10, 15, and
20 years of follow-up was 92.9%, 81.1%, 68.9%, and 47.5%, respectively. Of note, long-term survival after
myectomy was lower than for the general population [standardized mortality ratio (SMR) = 1.40, p < 0.005],
but still compared favorably with historical data from non-operated HCM patients. Survival after ASA at 2 and
5 years was 97.8% and 94.7%, respectively. Short-term (5 year) survival after ASA (SMR = 0.61, p = 0.48) was
comparable to that of the general population.
Conclusion: Long-term follow-up of septal reduction strategies in obstructive HCM reveals that surgical
myectomy and ASA are effective for symptom relief and LVOT gradient reduction and are associated with
favorable survival. While overall prognosis for the community HCM population is similar to the general
population, the need for surgical myectomy may identify a sub-group with poorer long-term prognosis.
We await long-term outcomes of more extensive myectomy approaches adopted in the past 10 years at
major institutions.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Further, the presence of left ventricular outﬂow tract (LVOT)
obstruction predicts increased mortality in HCM [1,2]. Accordingly,
interventional therapies that aim to decrease LVOT gradient, either
surgically or percutaneously have recently arisen. The long-term
impact of such septal reduction therapies has been little studied.
Surgical myectomy was ﬁrst described by Andrew Glenn
Morrow in 1961 and is the gold-standard treatment for medically
refractory obstructive HCM [3]. Surgeons at Stanford Hospital have
performed myectomy since 1972. In 1996, Robbins and colleaguesgy.
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be a safe and effective modality that improves New York Heart
Association (NYHA) functional class and symptoms. Others have
also reported mid-term follow-up for myectomy outcomes [5,6]. In
the mid-1990s, alcohol septal ablation (ASA) emerged as an
alternative interventional strategy for some patients with symp-
tomatic obstructive HCM [7,8]. In non-randomized studies, both
myectomy and ASA markedly improved functional classiﬁcation
and effectively reduced LVOT gradient [9–13].
In this paper, we report 20 years of post-procedural survival for
patients who underwent surgical septal reduction therapy
between 1972 and 2006 along with 5-year post-procedural
survival for those who underwent catheter-based alcohol septal
reduction. We compare long-term outcome with the expected
survival in the general population.
Methods
At Stanford University Medical Center between January 1972
and December 2006, 282 patients with severe medically refractory
symptoms resulting from obstructive HCM underwent interven-
tion for LVOT. For the surgical cohort, we chose to study the 192
patients who underwent an isolated surgical myectomy without
concomitant surgical procedure (most commonly mitral valve
repair or replacement). Twenty-one patients were lost to follow-up
after myectomy, leaving 171 patients in the isolated myectomy
cohort. ASA was ﬁrst performed at our institution in 2002. From
January 2002 to December 2006, 52 patients underwent ASAFig. 1. Echocardiographic assessment in hypertrophic cardiomyopathy (HCM). Paraster
patient with obstructive HCM (B); M-mode of the left ventricle at the mitral valve level i
absence of systolic anterior motion.because of co-morbidity or patient preference. No ASA patients
were lost to follow-up.
The diagnosis of HCM was based on standard clinical and
echocardiographic features, including myocardial hypertrophy in
the absence of other possible etiology. Before 1978, direct pressure
measurements were used to determine the degree of outﬂow tract
gradient. Since 1978, the degree of myocardial hypertrophy was
routinely assessed with M-mode echocardiography. Since 1984,
two-dimensional transthoracic echocardiography and continuous-
wave Doppler have been used. In accordance with American
Society of Echocardiography (ASE) guidelines, M-Mode, and 2D
methods of echocardiography were used in assessing left
ventricular (LV) diameters, shortening fraction, intraventricular
septum, and LV posterior wall thickness, and left-atrial end-
systolic diameter. Left ventricular hypertrophy was assessed and
measured in end-diastole using 2D echo (Fig. 1) [14].
HCM without signiﬁcant symptoms or without signiﬁcant
(>30 mmHg) resting or provokable LVOT gradient (during Valsalva
or exercise) was considered a contraindication for septal reduction
therapy. Prior to intervention and after extensive discussion of
treatment options, including risks and limitations, written
informed consent was obtained for all procedures.
The investigation conforms with the principles outlined in the
Declaration of Helsinki [15], and with the local legal requirements
and was approved by the Institutional Review Board at Stanford.
Although more recently a transition has been made toward
more extensive myectomy, for most patients in this historical
cohort septal myectomy was performed as described by Robbinsnal long-axis showing asymmetric hypertrophy (A); continuous wave Doppler in a
n a patient before (C) and after (D) a septal myectomy, demonstrating presence and
Table 1
Baseline characteristics of both treatment groups, pre-intervention (alcohol septal
ablation or surgical myectomy) NYHA, New York Heart Association; LVOT, left
ventricular outﬂow tract; ICD, implantable cardioverter deﬁbrillator.




Number of subjects 52 171
Age (years) 57.3  12.9 48.0  17.1
Sex (% men) 56 49
NYHA Class 2.99  0.35 2.74  0.65
Septal thickness (cm) 2.13  0.45 2.19  0.60
LVOT gradient-rest (mmHg) 67.1  26.9 67.4  43.4
LVOT gradient-provoked (mmHg)a 104.4  34.9 98.1  34.7
Mitral regurgitation 1.68  0.7 1.48  1.0
Systolic anterior motion (%) 95 85
ICD previously inserted (%) 11.5 0
a In the surgical myectomy group on 148 patients with a complete
echocardiographic assessment.
Table 2
Individualized procedural characteristics, including overlapping statistics including
rate of pacemaker placement, ICD placement, and short-term mortality for both
procedures.
Procedural Alcohol septal ablation Surgical myectomy
Alcohol amount (ml) 3.28  1.89 –
# Septals ablated 1.38  0.60 –
CK 1656  967 –
CK-MB 243  138 –
CPB time (min) – 55.0  16.3
Crossclamp time (min) – 23.2  10.6
Peri-procedure PPM (%) 7.7 6.4
Peri-procedure ICD (%) 1.9 0
30-day mortality (%) 0 2.9
CK, creatinine kinase; CK-MB, MB fraction creatinine kinase; CPB, cardiopul-
monary bypass; PPM, permanent pacemaker; ICD, implantable cardioverter
deﬁbrillator.
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the right coronary cusp of the aortic valve is retracted to expose the
interventricular septum. Two parallel incisions are made in
the septum, beginning 3–5 mm below the aortic annulus and
directed toward the left ventricular apex. The ﬁrst incision is made
just to the right of the midpoint of the right coronary cusp and
the second incision approximately 1 cm to the left, just below the
commissure between the left and right coronary cusps. The
intervening bar of muscle is then excised with countertraction
applied to the previously placed stay suture.
ASA was performed using previously described techniques
[10,16]. Brieﬂy, a temporary pacemaker lead is inserted in all
patients without permanent pacing devices. Measurements of
LVOT gradient are recorded at rest, after extrasystole, and during
Valsalva maneuver. An angioplasty balloon is introduced over a
coronary wire into the septal perforator artery. After inﬂation of
balloon, angiographic contrast is injected through the balloon
catheter to identify the course of the septal artery and conﬁrm lack
of reﬂux proximal to balloon. Echocardiography is performed and
gradients are measured during balloon inﬂation. Subsequently, a
small volume of ethanol is injected slowly through the balloon
catheter, followed by normal saline ﬂush. Ten minutes after the
last injection of ethanol, the balloon is deﬂated and removed.
Coronary angiography excludes left anterior descending artery
damage and veriﬁes septal artery occlusion. Hemodynamic
measurements are repeated. For patients with 50% reduction
of LVOT gradient, targeting of other septal perforators is
considered.
Implantable cardioverter deﬁbrillators (ICD) were placed in
accordance with standard guidelines at the time of the procedure,
be that for primary or secondary prevention of sudden cardiac
death. Patients with ICD’s prior to septal reduction therapy were
accounted for as well as those who had the devices inserted peri-
procedurally or after 30 days [17–20].
Follow-up details of NYHA functional class and echocardio-
graphic data, along with the need for repeat septal reduction
therapy, were obtained by reviewing patient records, from
information supplied by referring physicians, and mailed patient
questionnaires. The most recent vital status was obtained for each
of the study patients by interrogation of patient records and the
Social Security Death Index.
Continuous values are presented as a mean  standard devia-
tion. These continuous values were compared with Student’s t-test.
The observed mortality rates of the myectomy and ASA cohorts were
compared with expected mortality rates using the US Census Bureau
2002 national life-tables by means of a 1-sample log-rank test [21].
Comparisons with an age-matched population were carried out by
means of standardized mortality ratio (SMR) [21].
Cumulative event rates were calculated according to the
Kaplan–Meier method, with all-event or censoring times mea-
sured from the time of enrolment. The signiﬁcance of differences
in mortality between the groups was assessed with the use of the
log-rank test.
Results
The baseline characteristics of our cohort are presented
in Table 1. Analysis of the 5 years of data from the ASA cohort
and 20 years in the surgical myectomy cohort was performed, and
due to length of data, there are considerably fewer patients in the
ASA group vs myectomy group (52 vs 171, respectively; Table 1).
Subjects in the ASA group were generally older, with age ranges
that overlapped the subjects in the surgical groups (57.3  12.9
years vs 48.0  17.1 years), and were more likely to be male (56% vs
49%). The ASA cohort was similar to the myectomy cohort
with regards to initial NYHA class (2.99  0.35 vs 2.74  0.65),pre-procedural septal thickness (2.13  0.45 mm vs 2.19  0.60 mm),
resting (67.1  26.9 mmHg vs 67.4  43.4 mmHg) and provoked
LVOT gradients (104.4  34.9 mmHg vs 98.1  34.7 mmHg), mitral
regurgitation (1.68  0.7 vs 1.48  1.0), and presence of systolic
anterior motion of the mitral valve (95% vs 85%). Six patients in the
ASA group had previously undergone ICD implantation, and this was
done in accordance with the guidelines at the time of the procedure
and follow-up [17–20]. None of the patients in the surgical cohort had
ICDs placed prior to their procedure.
Analysis of the procedures, both ASA and surgical myectomy,
demonstrated similar characteristics to previously published data
(Table 2). For the ASA cohort, the amount of alcohol injected was
3.28  1.89 ml in a mean of 1.38  0.60 septal arteries. The peak rises
in creatinine kinase (CK) and creatinine kinase-MB (CK-MB) were
1656  967 IU/L and 243  138 IU/L, respectively. For the surgical
myectomy cohort, the mean cross-clamp time was 23.2  10.6 min,
with mean cardiopulmonary bypass time 55.0  16.3 min.
Peri-procedural outcomes were deﬁned as those appearing up
to 30 days after the procedure. Thirty-day events after the
procedures were comparable to published data (Table 2) [4,12,13].
The mean rate of pacemaker placement was 7.7% for the ASA
group and 6.4% for the surgical myectomy group. Likewise, the
percentage of implantable cardioverter deﬁbrillators placed peri-
procedurally was 1.9% in the ASA cohort and 0% in the surgical
myectomy group. Tamponade occurred in 1.9% of ASA patients. In
the ASA group, there were no non-localized, large, remote
myocardial infarctions or cerebrovascular events. Thirty-day
mortality was 0.0% in the ASA cohort and 2.9% in the surgical
myectomy cohort. No peri-procedural deaths after septal reduc-
tion procedures have occurred since 1994 at this institution.
Table 3
Post-procedural characteristics including length of follow-up and changes in
dimension and functional parameters.




Mean follow-up (years) 3.2 13.7
NYHA class 1.5  0.74 1.54  0.74
Septal thickness (cm) 1.55  0.30 1.78  0.66
LVOT gradient-rest (mm Hg) 23.9  29.4 11.2  16.4
LVOT gradient-provoked (mm Hg) 35.5  38.6 33.6  34.9
Mitral regurgitation 1.3  0.7 1.24  0.7
Systolic anterior motion (%) 69 61
NYHA, New York Heart Association; LVOT, left ventricular outﬂow tract.
Fig. 3. Comparison of survival of alcohol septal ablation cohort (dashed line) vs age-
matched controls from the US Census Bureau life table data (p = 0.48).
Fig. 4. Comparison of survival of alcohol septal ablation (ASA) vs surgical myectomy
cohorts (hazard ratio 0.991, chi square = 0.0003, p = 0.987).
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13.7 years for surgical myectomy, Table 3), hemodynamics and
symptoms post-procedurally were improved. Post-procedural
echocardiography demonstrated improved resting LVOT gradients
(67.1  26.9 mmHg to 23.9  29.4 mmHg for ASA, p < 0.001;
67.4  43.4 mmHg to 11.2  16.4 mm Hg for surgical myectomy,
p < 0.001), and provoked LVOT gradients (104.4  34.9 mmHg to
35.5  38.6 mmHg for ASA, p < 0.001; 98.1  34.7 mmHg to
33.6  34.9 mm Hg for surgical myectomy, p < 0.001). In both
cohorts, a signiﬁcant difference between the pre- and post-procedural
NYHA class was found (2.99  0.35 to 1.5  0.74 for ASA, p < 0.001,
2.74  0.65 to 1.54  0.74, p < 0.001). Values for mitral regurgitation
(MR) (1.68  0.7 to 1.3  0.7 for ASA, p = 0.003; 1.48  1.0 to
1.24  0.7 for surgical myectomy, p = 0.4) and percentage of patients
with systolic anterior motion (SAM) of the mitral valve (95%–69% for
ASA, p = 0.003; 85%–69% for surgical myectomy, p = 0.02) improved
with both therapies. These data are consistent with previously
published data [4,12,13,16].
At the end of follow-up, a total of 14 patients in the ASA cohort
had undergone ICD implantation, along with four patients in the
surgical group, according to guidelines [17–20].
After 5, 10, 15, and 20 years of follow-up, survival was 92.9%,
81.1%, 68.9%, and 47.5%, respectively. At a long-term follow-up, the
overall mortality of the myectomy cohort was signiﬁcantly greater
than that of an age-matched US general population (SMR = 1.40,
p < 0.005; Fig. 2).
At 2 and 5 years post-procedure, observed survival for the ASA
cohort was 97.8% and 94.7%, respectively (Fig. 3). Life-table
analysis vs age-matched controls revealed no difference between
the ASA cohort and the general population (SMR = 0.61, p = 0.48;
Fig. 3). Nevertheless, given the small number of patients andFig. 2. Comparison of survival of surgical myectomy cohort (dashed line) vs age-
matched controls from the US Census Bureau Data (p < 0.005).short-term follow-up, larger and longer-term study is needed to
make more deﬁnitive conclusions for this procedure.
Fig. 4 represents the long-term survival of patients treated with
ASA vs myectomy.
Discussion
In our paper, we present to our knowledge, the longest follow-
up data on patients undergoing septal reduction therapy, 20 years
(mean 13.7 years) for surgical myectomy and 5 years (mean of 3.2
years) for ASA. Historically, HCM patients were believed to exhibit
annual death rates as high as 3–6%, with fatal arrhythmias and
progressive heart failure contributing to poor outcome [22–24].
Although evidence has emerged that in unselected populations,
the presence of HCM alone does not signiﬁcantly adversely affect
survival, the presence of obstruction, severe symptoms, atrial
ﬁbrillation, or marked left ventricular wall thickness identiﬁed
populations at risk for increased mortality [1]. Maron and
colleagues showed that presence of LVOT at rest, deﬁned as basal
gradient of at least 30 mmHg, is a strong, independent predictor of
death [2]. Over the past four decades, septal myectomy has been
the gold standard for amelioration of LVOT gradient and relief of
symptoms in HCM patients [25–29]. Whether this improvement of
ventricular hemodynamics translates into survival beneﬁt has
been difﬁcult to determine based on lack of randomized controlled
trials. However, in a seminal retrospective study of 289 patients
D. Sedehi et al. / Journal of Cardiology 66 (2015) 57–62 61who underwent isolated surgical myectomy at the Mayo Clinic
between 1983 and 2001, Ommen and colleagues [5] reported
survival after myectomy at 5 and 10 years of 96% and 83%,
respectively, compared with 79% and 61%, respectively, in non-
operated patients with LVOT obstruction. Additionally, in that
series with mean follow-up 5.8 years, survival after surgical
myectomy did not differ signiﬁcantly from age- and sex-matched
general US population implying that surgical myectomy may
favorably affect the survival of HCM patients.
Since its introduction in 1994, ASA has emerged as an
alternative treatment strategy for obstruction in some HCM
patients with symptoms unrelieved by optimal medical therapy.
Although ASA may be associated with less complete resolution of
LVOT gradient and with higher rates of pacemaker requirement
than surgical myectomy (as high as 20% in some studies [6])
evidence has emerged that ASA is an effective procedure to lower
outﬂow gradient and improve symptoms [30–34].
In the present study, we describe the outcomes of surgical
myectomy and percutaneous ASA performed over 20 years and
5 years at Stanford Hospital for patients with symptomatic LVOT.
We present data from 171 patients who underwent isolated
septal myectomy and 52 patients who underwent ASA between
January 1972 and December 2006. Although the decision to
undergo myectomy or ASA was not randomized, the study
represents real-world integration of the clinical judgment of an
interdisciplinary team and patient preference at a tertiary
referral center involved in the critical assessment of treatment
modalities for HCM.
The principal ﬁndings of this nonrandomized, retrospective
report are the following. First, both myectomy and ASA markedly
improved NYHA functional classiﬁcation and effectively reduced
LVOT gradient. Secondly, 30-day mortality was low for both
cohorts (0% for ASA, 2.9% for myectomy) despite inclusion of data
from the early learning phase for each procedure at our institution.
With respect to procedural complications, the overall low rate
(7.7%) for pacemaker placement in the ASA cohort compares
favorably with data from previously published reports [5,6,31,32]
and may reﬂect incorporation of procedural modiﬁcations
(i.e. slower injection rate of alcohol) shown by Fernandes and
associates [35] to be associated with lower incidence of pacemaker
placement. Indeed, no peri-operative death has occurred since
1994 at this institution.
Thirdly, this investigation found no overall impairment in
survival after both myectomy and ASA on short-term follow-up
when compared to an age- and sex-matched general US popula-
tion. Short-term (5-year) survival was 92.9% after myectomy and
94.7% after ASA. These numbers compare favorably with the 5-year
survival of 79% reported by Ommen and colleagues [5] for non-
operated obstructive HCM patients. Although we cannot directly
assess the effect of these treatments on mortality, our data suggest
a potential early survival beneﬁt in septal reduction procedures,
both surgical and percutaneous, for properly selected patients
with symptomatic obstructive HCM. Moreover, concern that the
intramyocardial scar produced by ASA may contribute to
ventricular arrhythmias did not manifest in an early survival
disadvantage. Indeed, short-term survival was similar between
patients treated with myectomy and ASA. However, longer follow-
up will be necessary to clarify the risk of sudden death in this
cohort.
Lastly, long-term mortality after myectomy was higher than
for an age-matched general US population, but still compared
favorably with historical data from non-operated HCM patients.
We report survival after myectomy at 5, 10, 15, and 20 years at
92.9%, 81.1%, 68.9%, and 47.5%, respectively. Historical data on
outcomes of non-operated HCM patients include 10-year survival
of 61% as reported by Ommen and colleagues [5] for the subset ofpatients with basal LVOT gradient 30 mmHg. The lower mortality
in our myectomy cohort suggests that surgical relief of LVOT
obstruction in symptomatic patients may improve long-term
survival. Conversely, the failure of myectomy to completely
abolish a late survival disadvantage for HCM patients compared
to the general population may reﬂect such factors as incomplete
LVOT reduction, inability to abrogate diastolic dysfunction, or
continued arrhythmogenic potential. Alternatively, the presence of
obstruction may deﬁne a group with poorer long-term outcome
even in spite of therapy.
Limitations of the present study include its nonrandomized,
retrospective nature. Since cause of death was not available to us
in the majority of myectomy cases, we were not able to assess
survival free from HCM-related death. As a referral institution,
follow-up for all of our patients was not always as complete
as desired, and it is possible a small number patients may have
had unreported of septal reduction therapies which were
unaccounted for. As follow-up was also often directed by
referring physician, a complete record of ICD implantation is
also unavailable. Nevertheless, comparison of survival free from
all-cause mortality of our myectomy and ASA cohorts with the US
general population yielded data we regard as valid and clinically
relevant.
Conclusion
Results of the present study indicate that both myectomy and
ASA are safe and effective for relief of symptoms and reduction of
LVOT gradient in symptomatic HCM. Short-term survival after
myectomy and ASA is comparable to that of the US general
population, while long-term survival after myectomy appears
intermediate between the general population and non-operated
obstructive HCM patients. These survival trends suggest that
interventional treatment of LVOT gradient, both surgical and
percutaneous, may improve survival in patients with symptomatic
LVOT obstruction. However, longer follow-up is needed for a
deﬁnitive evaluation of the outcomes after ASA, and further
investigation into the long-term prognosis following more
extensive current myectomy techniques is warranted.
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